. 2026 Jun 5;26:962. doi: 10.1186/s12885-026-16216-7

Table 2.

Baseline characteristics and prior therapies

Number	Tumor type	Stage	Prior therapies and therapeutic effects
Number	Tumor type	Stage	Time before enrollment (month)	Treatment	Efficacy
T01001	Ovarian serous adenocarcinoma	IVB	≈ 45	Liposomal paclitaxel + Lobaplatin	PR
			≈ 41	Paclitaxel + Carboplatin	/
			36⁺	Surgical resection^*	/
			≈ 36	Paclitaxel + Carboplatin	PD
			25⁺	Gemcitabine	PD
			≈ 23	Etoposide + Bevacizumab	PD
			8⁺	PD-1 antibody	PD
T01003	Papillary thyroid carcinoma	I (high risk)	99⁺	Surgical resection^*	/
			95⁺	Radionuclide 131 iodine	/
			≈ 48	Surgical resection^#	/
			7⁺	Surgical resection^#	PD
T01005	Pancreatic adenocarcinoma	IV	4⁺	Surgical resection^*	/
			3⁺	Surgical resection^*	/
			2⁺	Paclitaxel (albumin-bound type) + Gemcitabine	PD
T02002	MELTVR	IIIB	4⁺	Surgical resection^*	/
T02002	MELTVR	IIIB	3⁺	Radiotherapy	PD

PR partial response, PD progressive disease, MELTVR myoepithelioma-like tumor of the vulvar region

* Tumor Resection

# Lymph Node Dissection

/ No data